Efficacy Study of Pre-operative IPH2201 in Patients With Squamous Cell Carcinoma of the Oral Cavity
Status:
Terminated
Trial end date:
2016-12-01
Target enrollment:
Participant gender:
Summary
The primary objective of this open label Phase Ib/II trial is to evaluate the clinical and
pharmacological activity of IPH2201 as a single-agent in treatment-naïve pre-operative
patients with operable Squamous Cell Carcinoma of the Oral Cavity .
43 patients are planned to be enrolled. The first 6 patients will receive IPH2201 at a dose
of 4 mg/kg q2w x 4. Subsequent patients will be treated at a dose of 10 mg/kg q2w x 4.
Standard loco-regional treatment with surgery followed by adjuvant therapy will be initiated
after the last administration of IPH2201.